Mesoblast 6-K attaches ASX Appendices 3G, 3H, 3Y, 2A

Rhea-AI Filing Summary

Mesoblast Limited furnished a Form 6-K noting that, on October 15, 2025, it filed several announcements with the Australian Securities Exchange. The report attaches and incorporates by reference four ASX documents: Appendix 3G (notification of issue, conversion or payment up of unquoted equity securities), Appendix 3H (notification of cessation of securities), Appendix 3Y (change of director’s interest notice), and Appendix 2A (application for quotation of securities).

The exhibits are labeled 99.1 through 99.4 and the report is signed by Company Secretary Niva Sivakumar.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of October 2025

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On October 15, 2025, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, notification of issue, conversion or payment up of unquoted equity securities (Appendix 3G) which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

On October 15, 2025, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, notification of cessation of securities (Appendix 3H) which is attached hereto as Exhibit 99.2, and is incorporated herein by reference.

On October 15, 2025, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, change of director’s interest notice (Appendix 3Y) which is attached hereto as Exhibit 99.3, and is incorporated herein by reference.

On October 15, 2025, Mesoblast Limited filed with the Australian Securities Exchange a new issue announcement, application for quotation of securities (Appendix 2A) which is attached hereto as Exhibit 99.4, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Niva Sivakumar

Niva Sivakumar

Company Secretary

Dated: October 15, 2025

INDEX TO EXHIBITS

Item
99.1						Appendix 3G of Mesoblast Ltd, dated October 15, 2025.
99.2						Appendix 3H of Mesoblast Ltd, dated October 15, 2025.
99.3						Appendix 3Y of Mesoblast Ltd, dated October 15, 2025.
99.4						Appendix 2A of Mesoblast Ltd, dated October 15, 2025.

FAQ

What did Mesoblast (MEOBF) report in its Form 6-K?

The company noted ASX filings dated October 15, 2025, and attached Appendix 3G, Appendix 3H, Appendix 3Y, and Appendix 2A as exhibits.

Which exhibits are included with Mesoblast’s (MEOBF) 6-K?

Exhibit 99.1: Appendix 3G; Exhibit 99.2: Appendix 3H; Exhibit 99.3: Appendix 3Y; Exhibit 99.4: Appendix 2A.

When were the ASX appendices filed by Mesoblast (MEOBF)?

They were filed on October 15, 2025, and are incorporated by reference in the 6-K.

Who signed Mesoblast’s (MEOBF) Form 6-K?

The report was signed by Company Secretary Niva Sivakumar.

What types of ASX notices did Mesoblast (MEOBF) attach?

A notification of new/unquoted equity securities (Appendix 3G), cessation of securities (Appendix 3H), change of director’s interest (Appendix 3Y), and application for quotation (Appendix 2A).